LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: 2-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 1 STUDY

被引：1

作者：

Mcinnes, I. ^{[1
]}

Kato, K. ^{[2
]}

Magrey, M. ^{[3
]}

Merola, J. F. ^{[4
,5
]}

Kishimoto, M. ^{[6
]}

Haaland, D. ^{[7
,8
]}

Chen, L. ^{[2
]}

Duan, Y. ^{[2
]}

Liu, J. ^{[2
]}

Lippe, R. ^{[9
]}

Wung, P. ^{[2
]}

机构：

[1] Univ Glasgow, Coll Med Vet & Life Sci, Glasgow, Scotland

[2] AbbVie Inc, Immunol, N Chicago, IL USA

[3] Case Western Reserve Univ, Cleveland, OH 44106 USA

[4] Brigham & Womens Hosp, Boston, MA 02115 USA

[5] Harvard Med Sch, Dermatol & Rheumatol, Boston, MA 02115 USA

[6] Kyoto Univ, Sch Med, Dept Nephrol & Rheumatol, Tokyo, Japan

[7] McMaster Univ, Hamilton, ON, Canada

[8] Waterside Clin, Rheumatol & Clin Immunol Allergy, Barrie, ON, Canada

[9] AbbVie Deutschland GmbH Co KG, Immunol, Wiesbaden, Germany

来源：

关键词：

D O I：

10.1136/annrheumdis-2022-eular.799

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

POS0081

引用

页码：260 / 261

页数：2